HIV incidence after pre-exposure prophylaxis initiation among women and men at elevated HIV risk: A population-based study in rural Kenya and Uganda

Oral pre-exposure prophylaxis (PrEP) is highly effective for HIV prevention, but data are limited on HIV incidence among PrEP users in generalized epidemic settings, particularly outside of selected risk groups. We performed a population-based PrEP study in rural Kenya and Uganda and sought to evalu...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:PLoS medicine 2021-02, Vol.18 (2), p.e1003492-e1003492
Hauptverfasser: Koss, Catherine A, Havlir, Diane V, Ayieko, James, Kwarisiima, Dalsone, Kabami, Jane, Chamie, Gabriel, Atukunda, Mucunguzi, Mwinike, Yusuf, Mwangwa, Florence, Owaraganise, Asiphas, Peng, James, Olilo, Winter, Snyman, Katherine, Awuonda, Benard, Clark, Tamara D, Black, Douglas, Nugent, Joshua, Brown, Lillian B, Marquez, Carina, Okochi, Hideaki, Zhang, Kevin, Camlin, Carol S, Jain, Vivek, Gandhi, Monica, Cohen, Craig R, Bukusi, Elizabeth A, Charlebois, Edwin D, Petersen, Maya L, Kamya, Moses R, Balzer, Laura B
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Oral pre-exposure prophylaxis (PrEP) is highly effective for HIV prevention, but data are limited on HIV incidence among PrEP users in generalized epidemic settings, particularly outside of selected risk groups. We performed a population-based PrEP study in rural Kenya and Uganda and sought to evaluate both changes in HIV incidence and clinical and virologic outcomes following seroconversion on PrEP. During population-level HIV testing of individuals ≥15 years in 16 communities in the Sustainable East Africa Research in Community Health (SEARCH) study (NCT01864603), we offered universal access to PrEP with enhanced counseling for persons at elevated HIV risk (based on serodifferent partnership, machine learning-based risk score, or self-identified HIV risk). We offered rapid or same-day PrEP initiation and flexible service delivery with follow-up visits at facilities or community-based sites at 4, 12, and every 12 weeks up to week 144. Among participants with incident HIV infection after PrEP initiation, we offered same-day antiretroviral therapy (ART) initiation and analyzed HIV RNA, tenofovir hair concentrations, drug resistance, and viral suppression (
ISSN:1549-1676
1549-1277
1549-1676
DOI:10.1371/journal.pmed.1003492